IP Library Granted Patent US 7,541,184
Granted Patent B2
US 7,541,184 · App. 10/762,210 · Granted Jun 2, 2009

Activation and expansion of cells

Assignee: Invitrogen Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,541,184
App. No.
10/762,210
Granted
Jun 2, 2009
Kind
B2
Abstract

The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells that maximizes the expansion of such cells to achieve dramatically high densities. In the various embodiments, cells are activated and expanded to very high densities in a short period of time. In certain embodiments, cells are activated and expanded to very high numbers of cells in a short period of time. Compositions of cells activated and expanded by the methods herein are further provided.

Claims (5)

1. A method for activating and expanding a population of regulatory T cells by simultaneous T cell concentration and cell surface moiety ligation, comprising:

a. contacting a population of cells wherein at least a portion thereof comprises regulatory T cells with a surface, wherein said surface is a surface of a paramagnetic particle and wherein said surface has attached thereto a first agent that ligates a first T cell surface moiety of a regulatory T cell, and the same surface has attached thereto a second agent that ligates a second moiety of said regulatory T cell; and

b. applying a magnetic force that predominantly drives T cell concentration and T cell surface moiety ligation;

thereby inducing activation and expansion of said regulatory T cell.

2. The method according to claim 1 wherein the first agent is an anti-CD3 antibody or an antigen-binding fragment thereof and the second agent is an anti-CD28 antibody or an antigen-binding fragment thereof.

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO 09452626 PREVIOUSLY RECORDED ON REEL 023882 FRAME 0551. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER SHOULD NOT HAVE BEEN RECORDED AGAINST THIS PATENT APPLICATION NUMBER. Recorded Nov 14, 2014
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 034217/0490 →
LIEN RELEASE Recorded Apr 9, 2013
From: BANK OF AMERICA, N.A.
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 030182/0461 →
MERGER Recorded Feb 3, 2010
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 023882/0551 →
SECURITY AGREEMENT Recorded Dec 5, 2008
From: LIFE TECHNOLOGIES CORPORATION
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 021975/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2006
From: XCYTE THERAPIES, INC.
To: INVITROGEN CORPORATION
Reel/Frame 018303/0117 →
ARTICLES OF INCORPORATION Recorded Sep 15, 2005
From: XCYTE THERAPIES, INC.
To: XCYTE THERAPIES, INC.
Reel/Frame 016536/0334 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2004
From: BERENSON, RONALD; LAW, CHE; BONYHADI, MARK; SAUND, NARINDER; CRAIG, STEWART; HARDWICK, ALAN; KALAMASZ, DALE; MCMILLEN, DAVID; CHANA, HARJINDER SINGH
To: XCYTE THERAPIES, INC.
Reel/Frame 014896/0726 →
Continuity (8)
Continuation In Part 1035030500 · Jan 22, 2003
Continuation In Part 1018746700 · Jun 28, 2002
Continuation In Part 1013323600 · Apr 26, 2002
Continuation In Part 0996026400 · Sep 20, 2001
Continuation In Part 0979423000 · Feb 26, 2001
Provisional Application 6024990200 · Nov 17, 2000
Provisional Application 6018478800 · Feb 24, 2000
Related Publication 20040241162A1 · Dec 2, 2004